Carvedilol increases atrial natriuretic peptide plasma levels in hypertensive patients

European Journal of Inflammation

Volumn 5, Issue 2, 2007, Pages 97-101

  Papadopoulos, P ^a   Kotridis, P ^a   Kokkas, B ^a,c   Koutsimanis, V ^a   Aidonidis, G ^a   Dadoush, G ^a   Gouli, O ^a   Karamouzis, M ^a   Kouyoumtzis, A ^a   Sakantamis G ^a   Hatseras, D ^b   Papadopoulos, C L ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c NONE   (Greece)

Author keywords

ANP; Carvedilol; Hypertension; adrenergic blockers

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL;

ADULT; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTIOXIDANT ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE; HEART SIZE; HUMAN; INOTROPISM; M MODE ECHOCARDIOGRAPHY; MALE; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34548101506     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X0700500206     Document Type: Article

References (22)

1. 1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology 4:165.
2. 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther. 12: 345.
3. Papadopoulos C.L., B. Kokkas and G. Anogiannakis. 2000. Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Int. J. Immunopathol. Pharmacol. 13:107.
4. Papadopoulos C.L. and B. Kokkas. 2003. Atrial natriuretic peptide contributes to the anti-hypertensive action of many drugs. Eur. J. Drug Met. Pharmacokinet. 28:55.
5. Bauriedel G., D. Skowasch and B. Hofling. 2000. Carvedilol as vasodilating -blocker for the treatment of hypertensive patients with peripheral vascular disease - a pilot study. Herz/Kreislauf 32:69.
6. Hama J., S. Nagata and T. Takenaka. 1995. Atrial natriuretic peptide and anti-hypertensive action due to beta-blockade in essential hypertensive patients. Angiology 46:511.
7. Kokkas B., P. Kotridis, M. Karamouzis et al. 2002. Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metab. Pharmacokin. 27:45.
8. Iwasaki T., A. Niwa and T. Shinoda. 1989 Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology 40:24.
9. Hollenberg M., J. Plum and P. Heering. 1991. Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension 9:819.
10. Geller D., M. Currie and K. Wakitani. 1984. Atriopeptides. Biochem. Biophys. Res. Commun. 120:333.
11. Rosmalen F., J. Horman and A. Tan. 1988. A sensitive radioimmunoassay of atrial natriuretic peptide in human plasma; some guidelines for clinical applications. Z. Kardiol. 77(S):20.
12. Karamouzis M., K. Mandroukas and D. Deligiannis. 1994. Changes in atrial natriuretic peptide (a-ANP) in long distance swimmers. Clin. Chem. Enzym. Comms. 6:191.
13. Lucarelli K., M. Iacoviello, P. Dessi-Fulgheri et al. 2002. Natriuretic peptides and essential hypertension. Ital. Heart J. 3(3):1085.
14. Balati B., H. Phung, F. Pousset et al. 2002. Relationships between the anti-hypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. Fundam. Clin. Pharmacol. 16:361.
15. Marteau J., M. Zaiou, G. Siest et al. 2005. Genetic determinants of blood pressure regulation. J. Hypertension 23:2117.
16. Shields P. and C. Glembotski. 1989. Regulation of atrial natriuretic factor-secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. Biol. Chem. 264:9322.
17. Ohta Y., K. Watanabe and M. Nakazawa. 2000. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J. Cardiovasc. Pharmacol. 36(S):19.
18. Yoshimoto T., M. Naruse and A. Tanabe. 1998. Potentiation of natriuretic peptide action by beta-adrenergic blocker carvedilol in hypertensive rats: a new anti-hypertensive mechanism. Endocrinology 139:81.
19. Papadopoulos C.L., B. Kokkas, P. Kotridis et al. 1995. Plasma atrial natriuretic peptide in essential hypertension after angiotensin coverting enzyme inhibition. Intern. J. Angiology 4:44.
20. Kotridis P., B. Kokkas, M. Karamouzis et al. 2002. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Pressure 11:91.
21. Kotridis P., B. Kokkas, P. Kyriakou et al. 2003. Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin. Eur. J. Drug Metabol. Pharmacokin. 28:143.
22. 1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Arterial Pressure (Gr) 1:201.